#HVO hVIVO PLC – Notice of Results April 7, 2026 – Posted in: hVIVO (HVO)

London, UK – 7 April 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2025 on Wednesday 15 April 2026. Analyst briefing A briefing open to equity research analysts will take place on Wednesday 15 April 2026 at 11.00am BST. To register and for more details please contact hVIVO@icrhealthcare.com. Investor presentation Yamin ‘Mo’ Khan,…

#HVO hVIVO PLC – Notice of Trading Update January 27, 2026 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the year ended 31 December 2025 on Thursday 29 January 2026. Investor presentation Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Thursday 29 January 2026 at 6pm. The…

#HVO hVIVO PLC – Appointment of Non-Executive Director December 18, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the appointment of Richard Cotton as Independent Non-Executive Director, effective today. Richard will also serve as Chair of the Audit Committee and as a member of the Remuneration and Nominations Committees. Richard brings extensive Board-level and financial expertise, including experience serving as Chair, Audit Chair and Senior Independent Director, as well as holding advisory…

#HVO hVIVO PLC – MSD to acquire Cidara November 27, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates its client Cidara Therapeutics, Inc (“Cidara” or the “partner”) which has entered into a definitive agreement under which Merck Sharp & Dohme LLC (“MSD”), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO’s unique capabilities in accelerating drug development and validates the…

#POLB Poolbeg Pharma PLC – Interim Results for the six months to 30 June 2025 September 29, 2025 – Posted in: Poolbeg Pharma (POLB)

29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Highlights & Updates • Cash balance of £10.0 million as at 30 June 2025, including £4.865 million gross proceeds raised as part of an oversubscribed and upsized fundraise • Cash runway extended into 2027, supporting the delivery of multiple…

#HVO hVIVO PLC – Interim results September 23, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2025 (“H1 2025”). Financial summary • Revenue of £24.2 million (H1 2024: £35.6 million), in line with expectations of £47 million for the full year · Includes £5.2 million and £0.3 million revenue contribution from CRS and Cryostore respectively • EBITDA (pre-exceptionals*) of…

#HVO hVIVO PLC – Notice of Results September 4, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2025 on Tuesday 23 September 2025. Analyst briefing A briefing open to equity research analysts will take place on Tuesday 23 September 2025 at 10.30am BST. To register and for more details please contact Walbrook PR on hvivo@walbrookpr.com. Investor presentation Yamin ‘Mo’…

#HVO hVIVO PLC – Proposed appointment of Chair July 29, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of customary due diligence procedures by the Company’s Nominated Adviser. It is intended that Shaun will join the Board on 1 September 2025. Shaun will bring substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales…

#HVO hVIVO PLC – Directorate Change July 18, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect. The Company can confirm that Ms James’ decision to resign from the Board is unrelated to the Company’s financial performance or outlook. The Company’s trading update for H1 2025 will be issued on 22 July…

#HVO hVIVO PLC – Notice of Trading Update July 9, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30 June 2025 on Tuesday 22 July 2025. Investor presentation Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Tuesday 22 July 2025…

1
2
3
4
Next
Last »